Cargando…
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
by the American Academy of Dermatology, Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151529/ https://www.ncbi.nlm.nih.gov/pubmed/32283230 http://dx.doi.org/10.1016/j.jaad.2020.04.030 |
| _version_ | 1783521271513874432 |
|---|---|
| author | Blaszczak, Alecia Trinidad, John C.L. Cartron, Alexander M. |
| author_facet | Blaszczak, Alecia Trinidad, John C.L. Cartron, Alexander M. |
| author_sort | Blaszczak, Alecia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7151529 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | by the American Academy of Dermatology, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71515292020-04-13 Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations Blaszczak, Alecia Trinidad, John C.L. Cartron, Alexander M. J Am Acad Dermatol JAAD Online by the American Academy of Dermatology, Inc. 2020-07 2020-04-10 /pmc/articles/PMC7151529/ /pubmed/32283230 http://dx.doi.org/10.1016/j.jaad.2020.04.030 Text en © 2020 by the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | JAAD Online Blaszczak, Alecia Trinidad, John C.L. Cartron, Alexander M. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations |
| title | Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations |
| title_full | Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations |
| title_fullStr | Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations |
| title_full_unstemmed | Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations |
| title_short | Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations |
| title_sort | adalimumab for treatment of hidradenitis suppurativa during the covid-19 pandemic: safety considerations |
| topic | JAAD Online |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151529/ https://www.ncbi.nlm.nih.gov/pubmed/32283230 http://dx.doi.org/10.1016/j.jaad.2020.04.030 |
| work_keys_str_mv | AT blaszczakalecia adalimumabfortreatmentofhidradenitissuppurativaduringthecovid19pandemicsafetyconsiderations AT trinidadjohncl adalimumabfortreatmentofhidradenitissuppurativaduringthecovid19pandemicsafetyconsiderations AT cartronalexanderm adalimumabfortreatmentofhidradenitissuppurativaduringthecovid19pandemicsafetyconsiderations |